Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer. [PDF]
Uekusa R +9 more
europepmc +1 more source
Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors. [PDF]
Zhang B +7 more
europepmc +1 more source
Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1. [PDF]
Morgan I +6 more
europepmc +1 more source
Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma. [PDF]
Toyohara Y +17 more
europepmc +1 more source
Poly(ADP-ribose)polymerase 2 is zinc-dependent enzyme and nucleosome reorganizer. [PDF]
Maluchenko N +8 more
europepmc +1 more source
Poly (ADP-Ribose) Polymerase 1 and 2 in B-Cell Lymphoma: Pathogenic Roles and Therapeutic Implications. [PDF]
Molina-Alvarez A +3 more
europepmc +1 more source
Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases. [PDF]
Call N, Tomkinson AE.
europepmc +1 more source
Poly (ADP-ribose) polymerase inhibitors in cancer therapy. [PDF]
Zhu Z, Shi Y.
europepmc +1 more source
A phase I clinical trial evaluating the effect of food on the pharmacokinetics of TSL-1502, a glucuronide prodrug of a novel oral poly (ADP-ribose) polymerase inhibitor, in healthy Chinese subjects. [PDF]
Zhou J +5 more
europepmc +1 more source

